Glenmark Pharma settles with Pfizer for Axitinib Tablets
Mumbai: Glenmark Pharmaceuticals Inc., USA (Glenmark) and Glenmark Pharmaceuticals Limited have reached a settlement agreement with Pfizer Inc., PF Prism C.V., and PF Prism IMB B.V. for Axitinib Tablets, 1 mg and 5 mg, the generic version of their Inlyta Tablets, 1 mg and 5 mg.
Axitinib is a cancer medicine. It works by blocking the action of the abnormal protein that signals cancer cells to multiply.
Glenmark had previously announced it received tentative approval by the United States Food & Drug Administration (U.S. FDA) for their generic Axitinib Tablets, 1 mg, and 5 mg on November 30, 2020.
According to IQVIA sales data for the 12‐month period ending September 2022, the Inlyta Tablets, 1 mg, and 5 mg market achieved annual sales of approximately $644.5 million*.
Read also: Glenmark gets CDSCO Panel nod to manufacture,market Lobeglitazone, Metformin antidiabetic FDC
Glenmark's current portfolio consists of 177 products authorized for distribution in the U.S. marketplace and 47 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Read also: Submit CT Protocol, Toxicity Report: CDSCO panel Tells Glenmark on respiratory drug combination
Glenmark Pharmaceuticals Limited is a global research-led pharmaceutical company with a presence across generics, specialty and OTC businesses and with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology, and oncology. The company has 10 world‐class manufacturing facilities spread across 4 continents and operations in over 80 countries. The company was listed on the Dow Jones Sustainability Index (DJSI), one of the world's most respected and widely accepted sustainability benchmarks, under the category of emerging markets (2021) for the fourth consecutive year.
Read also: Glenmark Pharma gets USFDA nod for generic version of Buphenyl tablets
